HK Stock Market Move | SIPAI HEALTH (00314) rose more than 46% in midday trading. The National Health Insurance Administration will add commercial health insurance innovative drugs to the catalogue.

SIPAI HEALTH rose more than 46% in midday trading and was up 29.53% at the time of publication, trading at HK$6.01 with a total transaction amount of HK$1.189 billion. On the news front, the National Healthcare Security Administration and the National Health Commission jointly issued 16 measures to support the high-quality development of innovative drugs. Among them, it is proposed for the first time to add an innovative drug catalog for commercial health insurance, focusing on high-value innovative drugs beyond the scope of medical insurance coverage, and supporting the full chain to develop the innovative drug industry. It is worth noting that SIPAI HEALTH previously announced that its Sipai Brokerage has reached a strategic cooperation agreement with Anrujiel to jointly develop customized insurance solutions in mainland China, promoting insurance product innovation and precise risk control. Anrujiel plans to establish subsidiaries/institutions in mainland China to cooperate with Sipai Brokerage in group and individual life insurance, health insurance, and related reinsurance business. It is reported that SIPAI HEALTH is one of the few domestic technology platforms that have both medical service management capabilities and health insurance business qualifications.